SCHEMBL19954636

SCHEMBL19954636

CC(C)(C)c1cc(C(F)(F)F)nn1C1CCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.39
MAPK13 O15264 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
MAPK14 Q16539 1/20 0.36
TGFBR1 P36897 6/20 0.35
TRPV1 Q8NER1 1/20 0.32
GAA P10253 1/20 0.32
PLAT P00750 1/20 0.32
PDE10A Q9Y233 1/20 0.32
KCNH2 Q12809 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
LRRK2 Q5S007 1/20 0.31
CHRNB2 P17787 1/20 0.31
CHRNB4 P30926 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA4 P43681 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22560184 0.93 TGFBR1 (0.38) NR3C2MAPK13MAPK12MAPK11MAPK14
SCHEMBL19954631 0.86 TGFBR1 (0.43) NR3C2TGFBR1PDE10ALRRK2
SCHEMBL25745871 0.85 MAPK13 (0.47) MAPK13MAPK12MAPK11MAPK14TRPV1
SCHEMBL24815018 0.83 MAPK13 (0.49) MAPK13MAPK12MAPK11MAPK14TRPV1
SCHEMBL19954641 0.83 NR3C1 (0.35) NR3C2TGFBR1HRH3
SCHEMBL19954623 0.83 CYP1A2 (0.32) TGFBR1LRRK2
SCHEMBL15069885 0.81 MAPK13 (0.40) MAPK13MAPK12MAPK11MAPK14LRRK2
SCHEMBL25745875 0.81 MAPK13 (0.44) NR3C2MAPK13MAPK12MAPK11MAPK14
SCHEMBL18164107 0.80 GAA (0.41) NR3C2MAPK13MAPK12MAPK11MAPK14
SCHEMBL19954603 0.80 TRPV4 (0.43) NR3C2TGFBR1GAAKCNH2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9914706-B2 N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2018-03-13 US disclosed